ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Growth in Short Interest

ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 2,160,000 shares, a growth of 5.4% from the October 15th total of 2,050,000 shares. Based on an average trading volume of 310,500 shares, the short-interest ratio is presently 7.0 days.

ANI Pharmaceuticals Stock Down 4.0 %

ANI Pharmaceuticals stock opened at $56.58 on Friday. The business has a fifty day moving average price of $58.40 and a 200-day moving average price of $61.31. ANI Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $70.81. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -102.87 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIPGet Free Report) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The company’s revenue was up 12.5% on a year-over-year basis. Equities research analysts forecast that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ANIP. Texas Permanent School Fund Corp increased its holdings in ANI Pharmaceuticals by 1.3% in the 2nd quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock worth $852,000 after buying an additional 178 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of ANI Pharmaceuticals by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 4.7% in the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after buying an additional 211 shares during the period. Simplicity Wealth LLC boosted its stake in shares of ANI Pharmaceuticals by 3.5% in the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 227 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in ANI Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after acquiring an additional 233 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of research analyst reports. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James upped their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $77.33.

Read Our Latest Stock Report on ANIP

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

See Also

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.